Blood and Marrow Transplant

Acute Myelogenous Lymphoma (AML)

Advanced Disease
- Matched Related or Unrelated Donor
- Mismatched Related or Unrelated

First (CR1) or Higher Remission
- Mismatched Unrelated

Post Hematopoietic Cell Transplantation (HCT)

BMT372
- Phase I Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/ T-Cell Depleted Graft
- PI: Meyer
- Sponsor: Stanford University

BMT342
- Phase III/III to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
- PI: Johnston
- Sponsor: Fred Hutchinson

BMT343
- Phase Ib T-Cell-Depleted Graft + Conventional & Regulatory T Cells in Advanced Hematologic Malignancies
- PI: Meyer
- Sponsor: Orca Biosystems

BMT377
- Phase Ib / III in Advanced Hematologic Malignancies Undergoing Allogeneic HCT with Either Orca-T or T-Cell-Depleted Graft w/ Additional Infusion of Conventional T Cells & Regulatory T Cells, or SoC Allogeneic Graft
- PI: Meyer
- Sponsor: Orca Biosystems Inc.

BMT391
- Phase II HLA Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide in Hematologic Malignancies
- PI: Arai
- Sponsor: National Marrow Donor Program (NMDP)

BMT338
- Phase I DonorGrafts Derived From OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
- PI: Meyer
- Sponsor: Orca Biosystems

BMT410
- A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia Who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation
- PI: Kennedy
- Sponsor: Vor Biopharma

KEY
- Optional Path
- Link
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu